Metabolic Stability and Biotransformation of Muscarinic Receptor Antagonists: An Integrated In Vitro Study

Background/Objectives: Metabolic stability is an important determinant of the pharmacokinetic properties of drug candidates, as metabolic instability may limit systemic exposure and lead to the formation of metabolites with distinct pharmacological properties. Here, we characterized the phase I metabolic stability and biotransformation pathways of five phenyl-substituted benzimidazole-based muscarinic acetylcholine receptor (mAChR) antagonists using an integrated in vitro and in silico approach. Methods: Metabolic stability, microsomal binding, and metabolite formation were investigated in human liver microsomes using liquid chromatography coupled to high-resolution and tandem mass spectrometry. GLORY, GLORYx, and FAME3R were used to rank possible sites of metabolism, while SwissADME was applied to estimate physicochemical and pharmacokinetic properties of the parent compounds and putative metabolites. Molecular docking was further used to explore potential effects of metabolic transformations on target interactions. Results: Compound 4 showed the most rapid metabolic turnover, whereas 1 displayed the highest intrinsic metabolic stability after correction for microsomal binding. Hydroxylation was the most frequently observed phase I transformation, with N-demethylation consistently detected across the series. Several putative metabolites were predicted to have properties consistent with P-glycoprotein (P-gp) substrate recognition and reduced brain penetration, whereas the parent compounds were not predicted to be P-gp substrates except for 4. Conclusions: The study defines major metabolic transformation pathways within this benzimidazole-based mAChR antagonist series and identifies metabolic liabilities that may be relevant to further compound optimization. The combined experimental and computational approach provides a framework for interpreting metabolic profiles and generating hypotheses for subsequent pharmacokinetic and structure activity investigations.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-10-30
DOI
https://doi.org/10.3390/ph19111714
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Metabolic Stability and Biotransformation of Muscarinic Receptor Antagonists: An Integrated In Vitro Study

Thierry Langer, Markus Spreitzer, Iva Spreitzer, Verena Pichler et al.
1 links
Pharmaceuticals
Pharmacogenetics and Drug Metabolism
article

Metabolic Stability and Biotransformation of Muscarinic Receptor Antagonists: An Integrated In Vitro Study

Thierry Langer, Markus Spreitzer, Iva Spreitzer, Verena Pichler, Marlon Millard, Judith Wackerlig, Patrick Mueller
article en

Abstract

Background/Objectives: Metabolic stability is an important determinant of the pharmacokinetic properties of drug candidates, as metabolic instability may limit systemic exposure and lead to the formation of metabolites with distinct pharmacological properties. Here, we characterized the phase I metabolic stability and biotransformation pathways of five phenyl-substituted benzimidazole-based muscarinic acetylcholine receptor (mAChR) antagonists using an integrated in vitro and in silico approach. Methods: Metabolic stability, microsomal binding, and metabolite formation were investigated in human liver microsomes using liquid chromatography coupled to high-resolution and tandem mass spectrometry. GLORY, GLORYx, and FAME3R were used to rank possible sites of metabolism, while SwissADME was applied to estimate physicochemical and pharmacokinetic properties of the parent compounds and putative metabolites. Molecular docking was further used to explore potential effects of metabolic transformations on target interactions. Results: Compound 4 showed the most rapid metabolic turnover, whereas 1 displayed the highest intrinsic metabolic stability after correction for microsomal binding. Hydroxylation was the most frequently observed phase I transformation, with N-demethylation consistently detected across the series. Several putative metabolites were predicted to have properties consistent with P-glycoprotein (P-gp) substrate recognition and reduced brain penetration, whereas the parent compounds were not predicted to be P-gp substrates except for 4. Conclusions: The study defines major metabolic transformation pathways within this benzimidazole-based mAChR antagonist series and identifies metabolic liabilities that may be relevant to further compound optimization. The combined experimental and computational approach provides a framework for interpreting metabolic profiles and generating hypotheses for subsequent pharmacokinetic and structure activity investigations.

PharmaceuticalsVol. 19(11)
University of Vienna (AT), University of Oslo (NO), Medical University of Vienna (AT)
Austrian Science Fund
Good health and well-being
Openalex Percentile: Top 10%
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon